Gerry Cox

Company: CANbridge Pharmaceuticals

Job title: Interim Chief Medical Officer, Chief Development Strategist

Seminars:

A Phase 1 Study of CAN106: A Novel, Long-Acting, Anti-C5 Monoclonal Antibody in Development for Complement-Mediated Diseases 11:40 am

Exploring data supporting anti-C5 mechanism of action Sharing Phase 1 single ascending dose clinical trial data in healthy volunteers Progressing into the clinic for paroxysmal nocturnal hemoglobinuria and other complement-mediated diseasesRead more

day: Track B - Day 1 AM